Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Gen-Probe Incorporated today announced that the US Food and Drug Administration (FDA) has granted an EUA (emergency use authorization) for its test, the Prodesse ProFlu-ST(TM), to be used in CLIA high complexity laboratories for the diagnosis of 2009 H1N1 influenza virus infection, aided by an algorithm that relies on seasonal influenza A/H1 virus and seasonal influenza A/H3 virus results, from a single sample in individuals who are diagnosed with influenza A by currently available FDA-cleared or authorized devices.
BioCryst Pharmaceuticals, Inc. announced financial results for the quarter and nine months ended September 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir.
Centene Corporation takes a proactive approach with education around how to prevent the influenza virus each year through its FluventionTM program.
Aetna today announced third-quarter 2009 operating earnings of $308.2 million, or $.69 per share, a 38 percent decrease from the prior-year quarter. Operating earnings exclude net realized capital gains (losses) and other items. The decrease in operating earnings per share from the prior-year quarter reflects a lower Commercial underwriting margin and a previously announced increase in pension expense partially offset by the impact of a lower number of shares outstanding year-over-year.
Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has entered into an agreement to acquire a 74.49% stake in ChinaVax, a Cayman Islands company that, as its sole business, holds a 13.27% stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen").
President Barack Obama declared H1N1 a national emergency this weekend, a status that will give the federal government greater flexibility and authority to contain the pandemic. But the current shortage of H1N1 vaccine underscores the severe lack of U.S. preparedness in responding to pandemics, whether through natural disease transmission or manmade bioterrorist attacks, according to a new video from the Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism.
The same reassuring voice on the telephone line when you fear you've had a poison emergency may be the same person answering your questions about the H1N1 flu pandemic.
Canadians are seeking credible information concerning the H1N1 (human swine flu) virus. As a leading Canadian source of ealth information, www.medbroadcast.com has launched a one-stop comprehensive national H1N1 (human swine flu) Influenza Health information centre (www.medbroadcast.com/H1N1). This information centre will help meet the needs of Canadians in search of useful, credible, and accurate H1N1 information.
Recent news articles regarding Swine Flu H1N1 have been widespread. The virulence of the strain among humans and its implications for pandemic disease in humans may lead to increased interest in homeopathic treatments for Swine Flu H1N1.
Pregnant women with significant symptoms of depression tend to have a stronger biological reaction to the seasonal flu vaccine than do women with lower depression levels, according to a new study.
GE Healthcare, one of the leading providers of healthcare information technology, today announced its selection by the Centers for Disease Control and Prevention (CDC) to provide extensive surveillance data for H1N1 and seasonal influenza activity throughout the United States.
A day after Senate Majority Leader Harry Reid proposed an 'opt-out' public option plan, health-care insurers' stocks climbed Tuesday," Dow Jones Newswires/The Wall Street Journal reports.
Supplies of the H1N1 (swine flu) vaccine are steadily increasing in the U.S. and should soon be more widely accessible in the next two weeks, the CDC said on Tuesday, CQ HealthBeat reports. During a press briefing, CDC Director Thomas Frieden said that 22.4 million vaccine doses are now available for states to order (Norman, 10/27). "We're beginning to get to significant increases in the availability," Frieden said.
"More than 22 million doses of swine flu vaccine are available now, and most Americans should soon find it easier to get their dose, U.S. health officials said Tuesday, " according to The Associated Press/The Washington Post.
Avisio, Inc. announces the signing of a definitive agreement to commercialize Instant Detect, a portable nano-based diagnostic technology. Avisio, a publicly-traded commercialization company with a mission to unlock the value of high-potential assets and transform them into high-value businesses, now has the worldwide license to commercialize Instant Detect's ground-breaking portable diagnostic sensory technology.
Micronics, Inc., a leading developer of point-of-care molecular diagnostic products, announced today that it has entered into a license agreement with Biosearch Technologies, Inc. (Biosearch) for the right to make, have made, use and sell Micronics’ products that incorporate Biosearch’s proprietary fluorophores and quencher dyes for nucleic acid assays. Under the terms of the worldwide license, Biosearch has granted Micronics a royalty-free use of certain of its chemistries for inclusion in Micronics’ infectious disease tests for sale in underdeveloped countries.
SciClone Pharmaceuticals, Inc. today announced a corporate restructuring that will reduce its U.S.-based workforce by approximately 17%, primarily in research and development. This restructuring follows the discontinuation of SciClone's RP101 phase 2 clinical trial announced on October 2, 2009.
Smiths Medical announced today that it has been selected for a contract award from the U.S. Department of Health and Human Services (HHS) for safety hypodermic syringes that could reach $10 million. The award is part of the government’s national flu pandemic preparedness efforts.
Preparing for this flu season, the American Society for Microbiology (ASM) PSAB Committee on Laboratory Practices has recently published a new interim algorithm providing guidance to clinical laboratories responsible for testing patients with respiratory illness for Influenza A, including H1N1.
An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.